title: Clinical performance of biodegradable polymer-coated sirolimus-eluting stents in unselected real-world population with coronary artery disease: results from the multicenter CORE Registry.
abstract: BACKGROUND
  The main aim of the CORE Registry was to evaluate clinical performance of the Supralimus-Core® biodegradable polymer-coated sirolimus-eluting cobalt-chromium stent (Sahajanand Medical technologies Pvt. Ltd., Surat, India) in unselected real-world patients.
  
  
  METHODS
  This was a multicenter, retrospective, non-randomized, single-arm study. A total of 376 consecutive patients treated with the Supralimus-Core® between April 2010 and June 2014 were enrolled. The primary-end point of the registry was major adverse cardiac events (MACE), which is a composite of cardiac death, target lesion revascularization (TLR), target vessel revascularization (TVR), myocardial infarction (MI) and stent thrombosis (ST). Clinical follow-up were scheduled at 30-day and 6-month.
  
  
  RESULTS
  The mean age of enrolled patients was 54.6±10.3 years. A total of 444 lesions were treated successfully with 457 stents (1.0±0.2 per lesion). The average stent length and diameter was 24.0±8.0 mm and 3.0±0.33 mm, respectively. Out of total patients, 300 (79.8%) were male. Diabetes, hypertension and chronic totally occluded lesions were found in 95 (25.3%), 102 (27.1%) and 125 (28.2%) patients, respectively, reflecting high-risk patients involvement. The incidence of MACE at 30-day and 6-month was found to be in 4 (1.1 %) and 4 (1.1%) patients, respectively. The TLR and ST was found in 1 (0.3 %) and 1 (0.3 %) patient respectively at 6-month follow-up.
  
  
  CONCLUSIONS
  The lower incidence of MACE, TLR and ST clearly delineates safety and efficacy of Supralimus-Core sirolimus-eluting stent in "real-world" patients with complex coronary lesions.
authors.affiliation: Banker Heart Institute, Vadodara, India - dnb@bankersheart.com.
authors.forename: Darshan
authors.initials: D
authors.lastname: Banker
authors.forename: Anand
authors.initials: A
authors.lastname: Ahuja
authors.forename: Harish
authors.initials: H
authors.lastname: Sanadhya
authors.forename: Chandra
authors.initials: C
authors.lastname: Purohit
authors.forename: Sharad
authors.initials: S
authors.lastname: Chandra
authors.forename: Rishi
authors.initials: R
authors.lastname: Sethi
authors.forename: Rashi
authors.initials: R
authors.lastname: Khare
authors.forename: Shivani
authors.initials: S
authors.lastname: Kothari
authors.forename: Ashok
authors.initials: A
authors.lastname: Thakkar
mesh_terms: D000328:Adult; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D011108:Polymers / Q000737:chemistry*; D011474:Prosthesis Design; D012042:Registries; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D020123:Sirolimus